Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- Cobicistat/elvitegravir/emtricitabine/tenofovir AF and cobicistat/elvitegravir/emtricitabine/tenofovir DF are recommended by the DHHS and EACS, and IAS-USA guidelines as alternative first-line HIV regimens[DHHS ART; EACS ART; IASUSA ART]
- In 2 phase III randomized clinical trials in treatment-naive patients, cobicistat/elvitegravir/emtricitabine/tenofovir AF was associated with noninferior Week 48 virologic efficacy, smaller increases in serum creatinine, less proteinuria, and smaller decreases in lower spine and hip bone mineral density vs cobicistat/elvitegravir/emtricitabine/tenofovir DF[Sax 2015]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content